No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib

Leuk Res. 2006 Feb;30(2):240-1. doi: 10.1016/j.leukres.2005.06.014. Epub 2005 Aug 2.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Drug Resistance
  • Female
  • Humans
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / genetics*
  • Mutation*
  • Protease Inhibitors / therapeutic use*
  • Proteasome Endopeptidase Complex / genetics*
  • Pyrazines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Protease Inhibitors
  • Pyrazines
  • Bortezomib
  • PSMB5 protein, human
  • Proteasome Endopeptidase Complex